

ASX Announcement

4 June 2020

Regeneus board change

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today announced that non-executive director Dr Glen Richards has resigned to allow him to focus on his other commitments.

Dr Richards joined the board of Regeneus as non-executive director in April 2015.

Regeneus' Independent Chairman Barry Sechos, thanked Dr Richards for his contribution.

"The Board would like to thank Glen for his tremendous efforts and deep business knowledge during his tenure as a Director. He has been an asset to Regeneus and we wish him all the best," said Mr Sechos.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications

T: 02 9237 2805

E: WE-AURegeneus@we-worldwide.com